Label: SODIUM CITRATE AND CITRIC ACID- sodium citrate and citric acid monohydrate solution

  • NDC Code(s): 84447-017-01, 84447-017-16
  • Packager: Belleview Biosciences LLC
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: unapproved drug other

DISCLAIMER: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

Drug Label Information

Updated April 8, 2025

If you are a consumer or patient please visit this version.

  • DESCRIPTION

    Sodium Citrate and Citric Acid Oral Solu􀆟 on, USP is a stable and pleasant-tas􀆟 ng systemic alkalizer containing sodium citrate and citric acid in a sugar-free
    base. It is a non-par􀆟 culate neutralizing buff er.
    Sodium Citrate and Citric Acid Oral Solu􀆟 on, USP contains in each teaspoonful (5 mL):
    SODIUM CITRATE Dihydrate 500 mg (0.34 Molar)
    CITRIC ACID Monohydrate 334 mg (0.32 Molar)
    Each mL contains 1 mEq sodium ion and is equivalent to 1 mEq bicarbonate (HCO3).
    INACTIVE INGREDIENTS: grape fl avoring, purifi ed water, sodium benzoate, sorbitol and sucralose.

  • CLINICAL PHARMACOLOGY

    Sodium citrate is absorbed and metabolized to sodium bicarbonate, thus acting as a systemic alkalizer. The effects are essentially those of chlorides before absorption and those of bicarbonates subsequently. Oxidation is virtually complete so that less than 5% of sodium citrate is excreted in the urine unchanged.

  • INDICATIONS AND USAGE

    Sodium Citrate and Citric Acid Oral Solution USP is an effective alkalinizing agent. It is useful in those conditions where long-term maintenance of an alkaline urine is desirable, and is of value in the alleviation of chronic metabolic acidosis, such as results from chronic renal insufficiency or the syndrome of renal tubular acidosis, especially when the administration of potassium salts is undesirable or contraindicated. This product is also useful for buffering and neutralizing gastric hydrochloric acid quickly and effectively.

    Sodium Citrate and Citric Acid Oral Solution USP is concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary pH around the clock, usually without the necessity of a 2 A.M. dose. This product alkalinizes the urine without producing a systemic alkalosis in the recommended dosage. This product is highly palatable, pleasant tasting, and tolerable, even when administered for long periods.

  • CONTRAINDICATIONS

    Patients on sodium-restricted diets or with severe renal impairment.

  • PRECAUTIONS

    Sodium Citrate and Citric Acid Oral Solution USP should be used with caution by patients with low urinary output unless under the supervision of a physician. This product should not be administered concurrently with aluminum-based antacids. Patients should be directed to dilute adequately with water and preferably, to take each dose after meals to avoid saline laxative effect. Sodium salts should be used cautiously in patients with cardiac failure, hypertension, impaired renal function, peripheral and pulmonary edema, and toxemia of pregnancy. Periodic examinations and determinations of serum electrolytes, particularly serum bicarbonate level, should be carried out in those patients with renal disease in order to avoid these complications.

  • ADVERSE REACTIONS

    Sodium citrate and citric acid oral solution on is generally well tolerated, without any unpleasant side eff ects, when given in recommended doses to patients with normal renal function on and urinary output. However, as with any alkalinizing agent, caution on must be used in certain patients with abnormal renal mechanisms to avoid development of alkalosis, especially in the presence of hypocalcemia.
    To report SUSPECTED ADVERSE REACTIONS, contact Kesin Pharma at 1-833-537-4679 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

  • OVERDOSAGE

    Overdosage with sodium salts may cause diarrhea, nausea and vomiting, hypernoia, and convulsions.

  • DOSAGE AND ADMINISTRATION

    Sodium Citrate and Citric Acid Oral Solution USP should be taken diluted in water, followed by additional water, if desired. SHAKE WELL BEFORE USING.

  • For Systemic Alkalization

    Usual Adult Dose

    2 to 6 teaspoonfuls (10 to 30 mL), diluted in 1 to 3 ounces of water, after meals and at bedtime, or as directed by a physician.

    Usual Pediatric Dose

    1 to 3 teaspoonfuls (5 to 15 mL), diluted in 1 to 3 ounces of water, after meals and at bedtime, or as directed by a physician. For children under two years of age, use is based on consultation with a physician.

  • As a neutralizing buffer

    3 teaspoonfuls (15 mL), diluted with 15 mL water, taken as a single dose, or as directed by a physician.

  • HOW SUPPLIED

    Sodium Citrate and Citric Acid Oral Solu􀆟 on, USP (colorless, grape fl avor) is supplied in the following oral dosage forms:
    NDC 81033-017-15: 15 mL unit dose cup
    NDC 81033-017-50: Case containing 100 unit-dose cups of 15 mL
    NDC 81033-017-30: 30 mL unit dose cup
    NDC 81033-017-51: Case containing 100 unit-dose cups of 30 mL

  • STORAGE:

    Keep tightly closed. Store at controlled room temperature, 20°-25°C (68°-77°F). Protect from freezing.

  • SPL UNCLASSIFIED SECTION

    Rx Only
    Packaged by:
    Kesin Pharma
    Oldsmar, Florida 34677
    Revised March 2025
    PI Rev. 01

  • PRINCIPAL DISPLAY PANEL - Bulk Drum

    NDC 84447-017-01

    Sodium Citrate and Citric Acid Oral Solution USP

    500 mg/334 mg per 5 mL

    **Sugar, Alcohol, Gluten and Dye Free**

    Each teaspoonful (5 mL) contains:

    Sodium Citrate Dihydrate..........500 mg

    Citric Acid Monohydrate............334 mg

    Rx ONLY

    Manufactured By:

    Belleview Biosciences LLC

    Brooksville, FL 34604

    Bulk Label

  • INGREDIENTS AND APPEARANCE
    SODIUM CITRATE AND CITRIC ACID 
    sodium citrate and citric acid monohydrate solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:84447-017
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    SODIUM CITRATE (UNII: 1Q73Q2JULR) (ANHYDROUS CITRIC ACID - UNII:XF417D3PSL) SODIUM CITRATE500 mg  in 5 mL
    ANHYDROUS CITRIC ACID (UNII: XF417D3PSL) (ANHYDROUS CITRIC ACID - UNII:XF417D3PSL) ANHYDROUS CITRIC ACID334 mg  in 5 mL
    Inactive Ingredients
    Ingredient NameStrength
    WATER (UNII: 059QF0KO0R)  
    SORBITOL (UNII: 506T60A25R)  
    SUCRALOSE (UNII: 96K6UQ3ZD4)  
    SODIUM BENZOATE (UNII: OJ245FE5EU)  
    Product Characteristics
    Color    Score    
    ShapeSize
    FlavorGRAPEImprint Code
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:84447-017-16473 mL in 1 BOTTLE; Type 0: Not a Combination Product04/08/2025
    2NDC:84447-017-01200000 mL in 1 DRUM; Type 0: Not a Combination Product04/08/2025
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    unapproved drug other04/08/2025
    Labeler - Belleview Biosciences LLC (131968803)
    Registrant - Belleview Biosciences LLC (131968803)
    Establishment
    NameAddressID/FEIBusiness Operations
    Belleview Biosciences LLC131968803manufacture(84447-017) , pack(84447-017) , label(84447-017)